C-Rad AB Class B (CRAD.B) AI Stock Analysis

• Market Cap: €1.11B
• Dividend Yield: N/A
• Average Volume (3M): 58.03K
• Price to Earnings (P/E): 43.2
• Beta (1Y): 0.56
• Revenue Growth: -5.80%
• EPS Growth: -65.99%
• Country: SE
• Employees: 99
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.38
• Shares Outstanding: 32,904,050
• 10 Day Avg. Volume: 15,927
• 30 Day Avg. Volume: 58,029
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: kr35.00 ▲(5.42% Upside)

C-Rad AB Class B's overall stock score is primarily influenced by its stable financial position and mild upward technical trend. However, concerns about declining revenue and profit margins, along with a high P/E ratio, weigh down the score. The lack of dividend yield and absence of recent earnings call data or notable corporate events further limit the stock's appeal.

C-Rad AB Class B Business Overview & Revenue Model

Company Description

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, a real-time tracking solution for particle therapy; Cyrpa laser positioning products; cAccessory, which automates the registration and validation of treatment accessories; and cPatient that automates patient identity validation without the need for contact between patients and devices. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.

How the Company Makes Money

C-Rad AB generates revenue primarily through the sale of its medical devices and software solutions to hospitals and healthcare facilities specializing in oncology treatment. The company has a diversified revenue model that includes direct sales, recurring revenue from service contracts, and maintenance agreements for its products. Key revenue streams include the sale of hardware systems such as the C-RAD Catalyst and Sentinel systems, as well as software licenses for their advanced imaging and treatment planning tools. Additionally, C-Rad benefits from strategic partnerships with major players in the healthcare industry, which can enhance market access and provide opportunities for collaborative product development. The company's focus on innovation and quality, combined with the growing demand for precision medicine in cancer treatment, positions it to capture significant market share and drive future growth.

C-Rad AB Class B Financial Statement Overview

Summary

C-Rad AB Class B has a stable financial position with a strong balance sheet and improving cash flow generation. However, recent declines in revenue and profit margins raise concerns about future growth and profitability.

Income Statement

C-Rad AB Class B shows a mixed performance in its income statement. The company has a strong gross profit margin, indicating efficient production and cost management. However, the net profit margin has declined in the TTM period, reflecting reduced profitability. Revenue growth has turned negative in the TTM, which is a concern, although previous years showed positive growth. The EBIT and EBITDA margins have also decreased, suggesting pressure on operating efficiency.

Balance Sheet

The balance sheet of C-Rad AB Class B is robust, with a low debt-to-equity ratio indicating minimal leverage and financial risk. The return on equity has decreased in the TTM, but it remains healthy, showing the company's ability to generate returns on shareholders' investments. The equity ratio is strong, reflecting a solid financial structure with a high proportion of equity financing.

Cash Flow

Cash flow analysis reveals a positive trajectory in free cash flow growth, indicating improved cash generation capabilities. The operating cash flow to net income ratio is moderate, suggesting that earnings are well-supported by cash flows. The free cash flow to net income ratio is over 1 in the TTM, highlighting strong cash conversion from profits. However, fluctuations in cash flow metrics over the years suggest potential volatility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	445.60M	469.00M	424.62M	301.33M	261.15M	221.63M
Gross Profit	251.40M	323.00M	287.21M	205.30M	170.23M	136.89M
EBITDA	71.80M	83.91M	53.10M	27.51M	45.71M	26.15M
Net Income	25.80M	56.45M	35.53M	7.48M	25.10M	14.37M
Balance Sheet
Total Assets	478.80M	489.36M	405.54M	339.17M	306.71M	270.52M
Cash, Cash Equivalents and Short-Term Investments	158.10M	150.90M	129.36M	121.90M	122.42M	108.05M
Total Debt	10.00M	9.00M	1.75M	4.08M	6.37M	7.44M
Total Liabilities	137.50M	164.37M	134.36M	96.63M	75.62M	70.73M
Stockholders Equity	341.30M	325.00M	271.18M	242.54M	231.09M	199.79M
Cash Flow
Free Cash Flow	44.71M	29.21M	16.45M	-1.53M	12.37M	11.66M
Operating Cash Flow	42.18M	30.08M	33.38M	9.69M	18.17M	18.45M
Investing Cash Flow	-11.70M	-6.67M	-16.93M	-11.22M	-5.80M	-6.78M
Financing Cash Flow	-6.50M	-7.04M	-5.69M	-2.38M	1.04M	68.01M

C-Rad AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 33.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CRAD.B, the sentiment is Positive. The current price of 33.2 is above the 20-day moving average (MA) of 33.20, above the 50-day MA of 32.29, and above the 200-day MA of 32.33, indicating a bullish trend. The MACD of 0.43 indicates Negative momentum. The RSI at 52.07 is Neutral, neither overbought nor oversold. The STOCH value of 54.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CRAD.B.

C-Rad AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	―	€1.11B	43.19	6.93%	―	-5.80%	-65.99%
PAX	―	$1.58B	142.11	2.64%	―	14.28%	-68.33%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEZI	―	$932.29M	-6.14	-36.55%	―	62.24%	21.16%
SEDANA	―	€1.05B	-25.90	-4.42%	―	13.48%	28.98%
BACTI.B	―	kr615.02M	―	-6.81%	―	-8.10%	62.08%
INTEG.B	―	€183.05M	-5.61	-18.35%	―	-5.63%	-1373.99%

C-Rad AB Class B Corporate Events

C-RAD AB Announces Share Repurchase Program to Optimize Capital Structure

C-RAD AB has announced a decision to repurchase up to 597,000 of its own class B shares, valued at a maximum of SEK 20 million, as part of a strategy to optimize its capital structure. This move, authorized by the 2025 Annual General Meeting, aims to reduce share capital by canceling the repurchased shares, potentially impacting the company’s financial targets and shareholder returns.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD AB Reports Strong Q3 2025 Earnings and Strategic Growth Initiatives

C-RAD AB reported a positive earnings trend for the third quarter of 2025, with a 12% increase in revenue and a 19% EBIT margin, driven by strong demand for their SGRT solutions and significant growth in their services sector. Despite geopolitical uncertainties affecting sales processes, the company is taking proactive steps to strengthen its market presence, with notable growth in the EMEA region and strategic partnerships aimed at enhancing patient safety in radiotherapy.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD Announces Leadership Transition with New Acting CEO

C-RAD has announced a leadership change with CEO Cecilia de Leeuw stepping down and CFO Linda Frölén taking over as acting CEO. Johan Danielsson has been appointed deputy CEO, and board member Peter Simonsbacka will consult to boost activity levels. The company is actively recruiting a new CEO. This transition aims to maintain the company’s momentum in the market, particularly in enhancing the quality of life for cancer patients through their SGRT technology.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD Expedites Q3 2025 Interim Report Approval

C-RAD has announced an advancement in the approval process for its interim report for the third quarter of 2025, following recent management changes. The board meeting to approve the report has been moved up, with distribution planned for October 21, 2025, and an investor presentation scheduled for October 23, 2025, indicating proactive steps in company operations and communication with stakeholders.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD to Present Q3 2025 Interim Report

C-RAD AB announced it will release its interim report for the third quarter of 2025 on October 23. The company will host a presentation on the same day, led by CEO Cecilia de Leeuw and CFO Linda Frölén, to discuss the report and answer questions. This event provides stakeholders with insights into C-RAD’s financial performance and strategic direction.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD Expands Czech Market Presence with Key Hospital Order

C-RAD has secured a significant order from Krajská Nemocnice Hospital in Liberec, Czech Republic, valued at 10 MSEK, to supply their advanced SGRT systems including Catalyst+™ HD and Sentinel™ 4DCT. This order enhances C-RAD’s presence in the Czech market, reinforcing their position as a trusted provider of radiation therapy solutions and paving the way for future collaborations in the region.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD Unveils Innovative Cancer Care Solutions at ASTRO 2025

C-RAD showcased its latest developments at ASTRO 2025, emphasizing tools that enhance cancer care by improving user experience and workflow efficiency. The introduction of Catalyst+ LITE offers clinics a scalable entry into Surface Guided Radiation Therapy, with features like high-precision motion management and tattoo-less patient setup. These innovations, including a new ergonomic workflow and six degrees of freedom patient alignment, aim to streamline clinical operations and reinforce C-RAD’s commitment to patient-centric care.

The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.

C-RAD and iRT Systems Partner to Enhance Radiotherapy Safety

C-RAD AB and iRT Systems GmbH have announced a partnership to enhance patient safety in radiotherapy by combining C-RAD’s surface-guided radiotherapy technology with iRT’s real-time beam verification system. This collaboration aims to provide clinical teams with advanced tools for automated workflows, quality assurance, and improved treatment fidelity, ultimately making radiation therapy safer and more efficient.